Business Wire

Dassault Systèmes Helps Define “Manufacturing in the Age of Experience” in Japan

Del

Dassault Systèmes (Euronext Paris: #13065, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, today announced that Dassault Systèmes is helping define and drive the digital transformation of industry in Japan during the “Year of Franco-Japanese Innovation,” an initiative launched in Tokyo on October 5, 2015 by the prime ministers of France and Japan to support cooperation between the two countries on innovation and scientific excellence.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151105006614/en/

Dassault Systèmes is hosting the event “Manufacturing in the Age of Experience” in Tokyo today, bringing together thought leaders and C-level executives from across Japan to address the challenges that Japanese industry is facing and their collective vision for its future. Together, they will explore how the use of virtual design, simulation, manufacturing and collaboration applications can help revitalize innovation, enable the shift from mass production to mass customization, encourage an open innovation platform and create new ecosystems with fab labs that will boost the local economy.

As one of the largest industrial countries in the world, Japan is now embarking on a highly-structured, five-year program—much like “Industry of the Future” in France and “Industry 4.0” in Germany—in order to embrace new digital concepts that can revolutionize industrial processes such as mass customization.

“The digital revolution that has taken place in design will soon take place at the manufacturing level and, by leveraging the possibilities offered by virtual universes, manufacturing can create a sustainable future,” said Bernard Charlès, President & CEO, Dassault Systèmes. “Industrial innovation integrates multiple digital concepts that are changing existing processes and creating a dynamic, holistic and more sustainable production model, including system-driven and interconnected production environments based on manufacturing-as-a-service, additive manufacturing and the use of new materials. Dassault Systèmes is participating in approximately 50 manufacturing programs around the world, including in Japan, to help bring together industrial and research ecosystems, combine their respective skills and focus their investments.”

A long-time technological partner to many of the largest industrial groups in Japan, Dassault Systèmes, with its 3DEXPERIENCE platform, brings state-of-the-art manufacturing solutions to mechanical, science-based and chemical industries worldwide.

“Manufacturing in the Age of Experience” is the first of many events that Dassault Systèmes will host during the “Year of Franco-Japanese Innovation.” The company was present at the official signing of this initiative, where it participated in a panel on digital innovation and demonstrated its 3DEXPERIENCity smart city project, Living Heart smart healthcare project and 3DEXCITE’s 3D marketing automation applications. Dassault Systèmes also has partnerships with a number of fab labs in Japan who are deploying the company’s 3DEXPERIENCE platform.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes’ collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 190,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass logo and the 3DS logo, CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, 3DSWYM, BIOVIA, NETVIBES and 3DEXCITE are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.

Contact information

Dassault Systèmes Press Contacts
Corporate / France
Arnaud MALHERBE, +33 (0)1 61 62 87 73
arnaud.malherbe@3ds.com
or
North America
Suzanne MORAN, +1 (781) 810 3774
suzanne.moran@3ds.com
or
EMEAR
Virginie BLINDENBERG, +33 (0) 1 61 62 84 21
virginie.blindenberg@3ds.com
or
China
Grace MU, +86 10 6536 2288
grace.mu@3ds.com
or
Japan
Yukiko SATO, +81 3 4321 3841
yukiko.sato@3ds.com
or
Korea
Myoungjoo CHOI, +82 10 8947 6493
myoungjoo.choi@3ds.com
or
India
Seema SIDDIQUI, +91 1244 577 100
seema.siddiqui@3ds.com
or
AP South
Tricia SIM, +65 6511 7954
tricia.sim@3ds.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45Pressemelding

VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great

Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41Pressemelding

Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180718005827/en/ Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21Pressemelding

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li

Xilam: H1 2018 Revenue: +50%18.7.2018 16:00Pressemelding

Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t

Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38Pressemelding

The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05Pressemelding

Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d